Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 28

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 28
---
 of third-party intellectual property rights, any of which could delay or impede their ability to meet our requirements.
An interruption in the supply of a key material could significantly delay our research and development process or increase our expenses
for commercialization or development of product. An interruption in the supply of a key material could significantly delay our research
and development process or increase our expenses for commercialization or development of products. Specialized materials must often be
manufactured for the first time for use in drug delivery technologies, or materials may be used in the technologies in a manner that
is different from their customary commercial uses. The quality of materials can be critical to the performance of a drug delivery technology,
so a reliable source that provides a consistent supply of materials is important. Materials or components needed for our drug delivery
technologies may be difficult to obtain on commercially reasonable terms, particularly when relatively small quantities are required
or if the materials traditionally have not been used in pharmaceutical products.

Our reliance on these third-party
suppliers also subjects us to other risks that could harm our business, including:

| ● | we are not currently a                                                                                                              
 major customer of many of our suppliers, and these suppliers may therefore give other customers’ needs higher priority than         
 ours;                                                                                                                               |
| ● | we may not be able to obtain                                                                                                        
 an adequate supply in a timely manner or on commercially reasonable terms;                                                          |
| ● | our suppliers, especially                                                                                                           
 new suppliers, may make errors in manufacturing that could negatively affect the efficacy or safety of our products or cause delays 
 in shipment;                                                                                                                        |
| ● | we may have difficulty                                                                                                              
 locating and qualifying alternative suppliers;                                                                                      |
| ● | switching components or                                                                                                             
 suppliers may require product redesign and possibly submission to the FDA or other similar foreign regulatory agencies, which could 
 impede or delay our commercial activities;                                                                                          |
| ● | one or more of our suppliers                                                                                                        
 may be unwilling or unable to supply components of our products;                                                                    |
| ● | the occurrence of a fire,                                                                                                           
 natural disaster or other catastrophe impacting one or more of our suppliers may affect their ability to deliver products to us in  
 a timely manner; and                                                                                                                |
| ● | our suppliers may encounter                                                                                                         
 financial or other business hardships unrelated to our demand, which could inhibit their ability to fulfill our orders and meet our 
 requirements.                                                                                                                       |

We may not be able to quickly
establish additional or alternative suppliers, if necessary, in part because we may need to